{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:25:55Z","timestamp":1774891555714,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Asociaci\u00f3n Colombiana de Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"},{"name":"Pontifical Xavierian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/objective<\/jats:title>\n                    <jats:p>The aim of the study was to assess the safety profile (defined as the percentage of patients with at least one hypoglycaemic event [more than 15 min with glucose levels &lt;3.0 mmol\/l as documented by continuous glucose monitoring] in the first 4 weeks of follow-up) for insulin degludec\/liraglutide (IDegLira) compared with multiple daily insulin injections (MDI) during the transition from hospital to an outpatient setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes. The study evaluated the percentage of patients with at least one hypoglycaemic event, the hypoglycaemia event density, the time in range (TIR 3.8\u201310 mmol\/l), the time below range (TBR &lt;3.0 or &lt;3.8 mmol\/l), and other glycaemic management metrics measured by continuous glucose monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-four patients were included in the analysis (32 in each group). They had a baseline HbA\n                      <jats:sub>1c<\/jats:sub>\n                      of 103 \u00b1 11.6 mmol\/mol (11.6\u00a0\u00b1\u00a01.7%) and age of 58\u00a0\u00b1\u00a012.4 years (means \u00b1 SD). The proportion of patients with at least one hypoglycaemic event (plasma glucose &lt;3.0 mmol\/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001), TBR &lt;3.8 mmol\/l (0.9% vs 2.9%;\n                      <jats:italic>p<\/jats:italic>\n                      =0.019) and TBR &lt;3.0 mmol\/l (0.6% vs 1.3%,\n                      <jats:italic>p<\/jats:italic>\n                      =0.008). The TIR 3.8\u201310 mmol\/l was higher in the IDegLira group (80.6% vs 69.7%;\n                      <jats:italic>p<\/jats:italic>\n                      =0.008). The findings were consistent regardless of baseline HbA\n                      <jats:sub>1c<\/jats:sub>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>IDegLira proved to be safer and more effective than MDI for individuals with type 2 diabetes who had suboptimal glycaemic control, aiding in their transition from hospital to outpatient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov NCT05767255<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>This research was funded by a grant from the Asociaci\u00f3n Colombiana de Endocrinolog\u00eda, Diabetes y Metabolismo (ACE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-025-06446-y","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:46:29Z","timestamp":1754340389000},"page":"1899-1907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insulin DEgludec\/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-3470","authenticated-orcid":false,"given":"Ana M.","family":"G\u00f3mez-Medina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-148X","authenticated-orcid":false,"given":"Diana C.","family":"Henao-Carillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina P.","family":"Villamil-Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaline","family":"G\u00f3mez-Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5401-0018","authenticated-orcid":false,"given":"Oscar M.","family":"Mu\u00f1oz-Velandia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-5589","authenticated-orcid":false,"given":"Carlos A.","family":"Yepes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma N.","family":"Chaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Pertuz-Noriega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-3620","authenticated-orcid":false,"given":"Pablo","family":"Aschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"6","key":"6446_CR1","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/dom.14347","volume":"23","author":"FJ Pasquel","year":"2021","unstructured":"Pasquel FJ, Urrutia MA, Cardona S et al (2021) Liraglutide hospital discharge trial: a randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge. Diabetes Obes Metab 23(6):1351\u20131360. https:\/\/doi.org\/10.1111\/dom.14347","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6446_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11892-017-0876-1","volume":"17","author":"AC Donihi","year":"2017","unstructured":"Donihi AC (2017) Practical recommendations for transitioning patients with type 2 diabetes from hospital to home. Curr Diab Rep 17(7):52. https:\/\/doi.org\/10.1007\/s11892-017-0876-1","journal-title":"Curr Diab Rep"},{"issue":"9","key":"6446_CR3","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.2337\/dc22-2426","volume":"46","author":"RJ Galindo","year":"2023","unstructured":"Galindo RJ, Moazzami B, Scioscia MF et al (2023) A randomized controlled trial comparing the efficacy and safety of IDegLira versus basal-bolus in patients with poorly controlled type 2 diabetes and very high HbA1c \u22659\u201315%: DUAL HIGH trial. Diabetes Care 46(9):1640\u20131645. https:\/\/doi.org\/10.2337\/dc22-2426","journal-title":"Diabetes Care"},{"issue":"1","key":"6446_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1900\/RDS.2023.19.14","volume":"19","author":"H Vargas-Uricoechea","year":"2023","unstructured":"Vargas-Uricoechea H, Frias JP, Vargas-Sierra HD (2023) Fixed-ratio combinations (basal insulin plus GLP-1RA) in type 2 diabetes. An analytical review of pivotal clinical trials. Rev Diabet Stud 19(1):14\u201327. https:\/\/doi.org\/10.1900\/RDS.2023.19.14","journal-title":"Rev Diabet Stud"},{"issue":"9","key":"6446_CR5","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.2016.1252","volume":"315","author":"I Lingvay","year":"2016","unstructured":"Lingvay I, P\u00e9rez Manghi F, Garc\u00eda-Hern\u00e1ndez P et al (2016) Effect of insulin glargine up-titration vs insulin degludec\/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315(9):898\u2013907. https:\/\/doi.org\/10.1001\/jama.2016.1252","journal-title":"JAMA"},{"issue":"1","key":"6446_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367(1):20\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1114248","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"6446_CR7","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc24-S006","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 6. Glycemic goals and hypoglycemia: standards of care in diabetes \u2013 2024. Diabetes Care 47(Suppl 1):S111\u2013S125. https:\/\/doi.org\/10.2337\/dc24-S006","journal-title":"Diabetes Care"},{"issue":"1","key":"6446_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino T, Alexander CM, Amiel SA et al (2023) Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol 11(1):42\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(22)00319-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6446_CR9","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2337\/dc17-1114","volume":"41","author":"LK Billings","year":"2018","unstructured":"Billings LK, Doshi A, Gouet D et al (2018) Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care 41(5):1009\u20131016. https:\/\/doi.org\/10.2337\/dc17-1114","journal-title":"Diabetes Care"},{"issue":"3","key":"6446_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12020-023-03543-z","volume":"83","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li X, Zheng Y, Wang X, Wang X (2024) IDegLira for type 2 diabetes: a systematic review and meta-analysis. Endocrine 83(3):648\u2013658","journal-title":"Endocrine"},{"issue":"1","key":"6446_CR11","first-page":"145","volume":"15","author":"I Romano","year":"2024","unstructured":"Romano I, Serra R (2024) Use of IDegLira to intensify, simplify, and increase appropriateness of type 2 diabetes therapy: a real-life experience. Diabetes Ther Res Treat Educ Diabetes Relat Disord 15(1):145\u2013154","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"6","key":"6446_CR12","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1007\/s12325-022-02138-w","volume":"39","author":"Y Kawaguchi","year":"2022","unstructured":"Kawaguchi Y, Miyamoto S, Hajika Y et al (2022) Efficacy of IDegLira versus IDegAsp therapy in patients with type 2 diabetes: a randomized crossover study by isCGM. Adv Ther 39(6):2688\u20132700. https:\/\/doi.org\/10.1007\/s12325-022-02138-w","journal-title":"Adv Ther"},{"issue":"3","key":"6446_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00592-024-02361-7","volume":"62","author":"ME Malighetti","year":"2025","unstructured":"Malighetti ME, Molteni L, Orsi E et al (2025) IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study. Acta Diabetol 62(3):367\u2013374. https:\/\/doi.org\/10.1007\/s00592-024-02361-7","journal-title":"Acta Diabetol"},{"issue":"12","key":"6446_CR14","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1111\/dom.13851","volume":"21","author":"E Miller","year":"2019","unstructured":"Miller E, Doshi A, Gr\u00f8n R et al (2019) IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. Diabetes Obes Metab 21(12):2643\u20132650. https:\/\/doi.org\/10.1111\/dom.13851","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6446_CR15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13300-024-01593-8","volume":"15","author":"A Ram\u00edrez-Rinc\u00f3n","year":"2024","unstructured":"Ram\u00edrez-Rinc\u00f3n A, Henao-Carrillo D, Omeara M et al (2024) SPIRIT: assessing clinical parameters associated with using IDegLira in patients with type 2 diabetes in a real-world setting in Colombia. Diabetes Ther 15(7):1535\u20131545","journal-title":"Diabetes Ther"},{"issue":"11\u201312","key":"6446_CR16","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s13300-022-01327-8","volume":"13","author":"B Tramunt","year":"2022","unstructured":"Tramunt B, Disse E, Chevalier N et al (2022) Initiation of the fixed combination IDegLira in patients with type 2 diabetes on prior injectable therapy: insights from the EASY French real-world study. Diabetes Ther 13(11\u201312):1947\u20131963","journal-title":"Diabetes Ther"},{"issue":"1","key":"6446_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12902-022-01139-8","volume":"22","author":"S Sz\u00e9pk\u00fati","year":"2022","unstructured":"Sz\u00e9pk\u00fati S, Bandur S, Kov\u00e1cs G et al (2022) Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study. BMC Endocr Disord 22(1):229. https:\/\/doi.org\/10.1186\/s12902-022-01139-8","journal-title":"BMC Endocr Disord"},{"issue":"Suppl 1","key":"6446_CR18","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.2337\/dc24-S008","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes \u2013 2024. Diabetes Care 47(Suppl 1):S145\u2013S157. https:\/\/doi.org\/10.2337\/dc24-S008","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06446-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:44:08Z","timestamp":1774889048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06446-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6446"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06446-y","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors' affiliations were corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Medical writing in English and editorial assistance were provided by Festina Lente (Medellin, Colombia) and funded by Novo Nordisk Colombia. The collaboration agreement between the Pontificia Universidad Javeriana and Springer Nature enabled the open access publication. The authors assume full responsibility for the content and conclusions expressed in this manuscript. Novo Nordisk did not influence the content of this publication nor participate in the study design, data collection, analysis, interpretation or review, or in any stage of the publication process.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The datasets generated or analysed for the current study are available upon reasonable request from the sponsor institution (Hospital Universitario San Ignacio).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Open Access funding provided by Colombia Consortium. This research was funded by a grant from the Asociaci\u00f3n Colombiana de Endocrinolog\u00eda, Diabetes y Metabolismo (ACE).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AMG-M received speaker fees from Novo Nordisk, Astra Zeneca, Sanofi, Eli Lilly, Boehringer Ingelheim, Abbott and Medtronic. DCH-C received speaker fees from Novo Nordisk, Sanofi and Abbott. The remaining authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"AMG-M conceived the study. AMG-M, DCH-C, LPV-C, OMM-V, CAY, YG-Q and PA designed the study, analysed the data and critically reviewed the protocol. SNC and CEP-N participated in the acquisition of data and database elaboration. All authors contributed to the final version of the manuscript, and approved the version to be published. AMG-M is the guarantor of this work, and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}